The Eating Disorders Alliance is raising concerns about the accessibility and regulation of GLP-1 RA medications, particularly through telehealth clinics. They argue that patients should undergo mandatory comprehensive medical assessments before being prescribed these weight loss drugs. The alliance's concerns are backed by the Butterfly Foundation's observations of a rising number of callers worried about GLP-1 receptor agonists. This issue is exacerbated by the fact that many patients access these medications through online-only telehealth clinics like Juniper or Mosh, which operate outside the MBS and PBS, making data collection challenging.
Clinical psychologist and director of the National Eating Disorder Collaboration, Dr. Sarah Trobe, highlights the challenge of patients with eating disorders not disclosing their condition due to a desire for medication access. The alliance has long been concerned about the inadequate regulation of these medications, as evidenced by the recent case of a woman who, despite a history of disordered eating and mental health issues, was prescribed GLP-1 RAs through a telehealth service, leading to a relapse and hospital admission. The company involved, Eucalyptus, has defended its practices, claiming extensive screening and mandatory training.
However, the Eating Disorders Alliance advocates for stricter government scrutiny and regulations for doctors operating outside the MBS, along with mandatory comprehensive medical assessments in telehealth settings for individuals seeking weight loss medications. Dr. Trobe emphasizes the importance of a thorough evaluation, including physical health assessments, to ensure informed care and prevent potential risks associated with GLP-1 medications, especially for those with mental health conditions.
